Glecaprevir/Pibrentasvir Concentrations in the Breastmilk of Lactating Women
L Madeline McCrary1, Hideji Fujiwara1,2, John Robinson1,2
1Division of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Abstract:
In this prospective pharmacokinetic study of women undergoing chronic hepatitis C virus treatment with glecaprevir/pibrentasvir, the mean glecaprevir and pibrentasvir concentrations in breastmilk were 0.63% and 4.23% of maternal plasma concentrations, with a mean relative infant dose of 0.02% and 0.06%, respectively.

